On November 18, PEGBIO CO-B fell 5.26% in Regular Trading, trading at HK$2.705, with turnover of HK$7.4769 million.
The latest identifiable catalyst is a continued pullback after the company’s core product Paidakang was added to the 2026 National Reimbursement Drug List, with earlier gains fading as short-term profit-taking emerged following the policy-driven rally.
Background disclosures show Paidakang, or visepegenatide injection, is the company’s once-weekly GLP-1 therapy for blood glucose control in adults with type 2 diabetes and its first approved innovative drug. The company previously entered an exclusive mainland China commercialization partnership with Shanghai Tengrui Pharmaceutical and set a cumulative sales target of more than RMB10 billion. NRDL inclusion is expected to improve affordability, hospital access, clinical promotion and market coverage, but the stock has recently turned volatile as the initial benefit was priced in.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments